leisure time -WSS

leisure time

author：hotspot 2025-09-30 18:58:54 - browse：8751

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Why Sanofi got shellacked over its spinoff

WSS

Europe sees delivery challenges ahead on Alzheimer's therapies

Does aspartame cause cancer? What new WHO guidance says

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

Diversifying clinical trials isn't enough to close racial gaps: study

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

WHO may add ‘noma' to its list of neglected tropical diseases

focus

leisure time

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

leisure time

Walensky prepares to leave CDC — and Congress — behind

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

Alkermes shareholders re

J&J expands global access to TB drug amid advocacy campaign

Bright Health sells Medicare Advantage business to Molina

Georgia court denies Trump's request to quash DA's 2020 election probe

Sports medicine is finally prioritizing gender equality

Grail faces three suits alleging harassment, retaliation

As demand for Covid shots wanes, Moderna seeks its next success

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

hotspot

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Cassava reveals details — and problems — with Alzheimer's study

Federal judge rules Oregon’s tough new gun law is constitutional

Grail faces three suits alleging harassment, retaliation

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

focus

leisure time

leisure time

focus